ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1393	National Cancer Institute	Html	en	Cancer-Related Post-traumatic Stress (PDQ®)–Health Professional Version	Expert-reviewed information summary about post-traumatic stress and related symptoms in cancer patients, cancer survivors, and their family members. Assessment and treatment of these symptoms are discussed.	traumatic event 0.311819 cancer treatment 0.301201 post-traumatic stress disorder 0.298884 study 0.281873 full-criteria PTSD group 0.329802 PTSD trauma model 0.338033 PTSD criteria 0.318826 cancer experience 0.272753 cancer treatment received. 0.271124 intrusive thoughts 0.407892 PTSD Checklist-Civilian Version 0.325724 broad PTSD symptom 0.316477 PTSD trauma 0.338289 specific PTS symptoms 0.273748 PTSD immediately postsurgery 0.349332 PTSD symptoms 0.490814 current PTSD 0.319607 early-stage breast cancer 0.412505 adult cancer patients 0.298142 child cancer survivors 0.27606 PTS symptoms 0.347359 diagnostic criteria 0.511308 PTSD patients 0.326115	bone marrow transplant 0.330974 mild-to-moderate cancer-related PTSD 0.358971 structured clinical interview 0.302585 PTSD-like symptoms 0.416348 patients 0.448951 cancer patients 0.334316 post-traumatic symptoms 0.263192 PTSD diagnostic criterion 0.407584 breast cancer 0.98286 DSM-IV PTSD syndrome 0.373544 breast cancer survivors 0.33396 acute stress disorder 0.277841 lifetime PTSD 0.33232 PTSD 0.797398 symptoms 0.617748 DSM-IV PTSD 0.41474 PTSD module 0.291206 cancer survivors 0.345932 stress symptoms 0.286797 metastatic breast cancer 0.268733 precise PTSD symptoms 0.406493 DSM-IV diagnostic criteria 0.337351 early-stage cancer 0.260629	CLICK HERE
1448	National Cancer Institute	Html	en	Bladder and Other Urothelial Cancers Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for bladder cancer.	bladder cancers 0.459113 individual developing bladder 0.462762 bladder cancer patients 0.501836 Cancer Statistics Review 0.390961 transitional cell carcinoma 0.372436 American Cancer Society 0.389675 bladder cancer 0.911425 Bladder histological changes 0.431525 bladder cancer outcome 0.469139 bladder cancer cases 0.467655 Malignant bladder tumors 0.429947 bladder neoplasms 0.417201 bladder tumours 0.413309 repetitive hematuria screening 0.375531 bladder cancer risk 0.493294 bladder tumors 0.476533 superficial bladder cancer 0.470192 hematuria screening studies 0.380947 bladder toxicity 0.421878 Natl Cancer Inst 0.460204 newly diagnosed bladder 0.471386 Bladder Cancer Group 0.465328 metastatic bladder cancer 0.508614 neuropathic bladder 0.420139 et al. 0.424244	SEER Cancer Statistics 0.388904 bladder carcinogenesis 0.425543 bladder wall 0.415168 bladder cancer mortality 0.489217 bladder tumor antigen 0.4299 bladder cancer. 0.44027 urothelial bladder cancer 0.487451 Cancer Epidemiol Biomarkers 0.435283 urothelial cancer 0.372416 smoking related bladder 0.437945 PUBMED Abstract 0.468199 hematuria home screening 0.413339 bladder cancer case-fatality 0.488876 invasive bladder cancer 0.504621 Superficial bladder tumor 0.43348 National Cancer Institute 0.389198 Bladder cancer incidence 0.470999 bladder malignancies 0.448894 Epidemiol Biomarkers Prev 0.405245 bladder tumor incidence 0.430849 Bladder cancer screening 0.490371 Abstract 0.469966 recurrent bladder tumors 0.444789 urinary bladder cancer 0.487624	CLICK HERE
1643	National Cancer Institute	Html	en	Mistletoe Extracts (PDQ®)–Patient Version	Mistletoe extracts have been studied in Europe as a treatment for many illness including cancer. Read about the use of mistletoe therapy in cancer patients and the results of clinical trials in this expert-reviewed summary.	cancer treatment 0.498733 mistletoe extracts 0.84177 European mistletoe species 0.59742 cancer cell growth 0.480977 Cancer Complementary 0.499093 white blood cells 0.478127 clinical trials 0.814026 injectable mistletoe extracts 0.584449 cancer information summary 0.547122 alternative cancer therapies 0.496047 National Center 0.487589 CAM cancer research 0.482862 mistletoe extract products 0.586898 patients 0.558663 cancer patients 0.50887 body fight cancer 0.488697 certain European countries 0.486934 mistletoe 0.936372 Integrative Health 0.4867 NCI PDQ cancer 0.515414 alternative medicine therapies 0.509636 cancer information database 0.494234 randomized clinical trials 0.496538 Therapies Editorial Board 0.492111	metastatic pancreatic cancer 0.479516 mistletoe plant 0.574134 injectable mistletoe 0.604199 treatment 0.516928 Complementary Therapies Editorial 0.512225 human cancer cells 0.481784 Drug Administration 0.544399 Cancer Information Specialist 0.48946 cancer cells 0.492698 PDQ cancer information 0.630287 Cancer Information Service 0.543474 mistletoe extract 0.769423 mistletoe dose 0.56553 treatment clinical trials 0.481986 National Cancer Institute 0.675985 studies 0.476699 alternative medicine 0.586786 European mistletoe 0.657219 mistletoe products 0.583934 mistletoe lectins 0.572067 cancer clinical trials 0.506662 cell lung cancer 0.478767 alternative therapies 0.505915 cancer information summaries 0.526674	CLICK HERE
1728	National Cancer Institute	Html	en	End-of-Life Care for People Who Have Cancer	A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life.	family members 0.618911 family caregivers 0.218961 advance directives 0.30098 patients 0.4187 people 0.36964 life 0.365064 caregivers 0.584429	health care team 0.768547 person 0.99495 patient 0.848579 hospice care 0.29663 Related Resources section 0.284122 loved ones 0.266236 cancer 0.462571	CLICK HERE
1819	National Cancer Institute	Html	es	Tratamiento del tumor de Wilms y otros tumores renales infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del tumor de Wilms y otros tumores renales infantiles.	wilms tumor 0.821427 wilms tumours 0.50463 anomalías congénitas 0.435681 gen blm 0.427775 gen oncoinhibidor 0.442787 gen oncosupresor h19 0.43309 gen drosha 0.426257 anomalías cardíacas congénitas 0.422372 Ahmed HU 0.422578 tumores renales 0.459976 gen ctr9 0.450784 gen cdkn1c 0.42907 renal tumours 0.428247 afección gen fenotipo 0.433197 síndrome wagr 0.961757 gen pax6 0.452923 Gen Wilms tumor 0.633712 cánceres renales 0.430685 síndrome congénito 0.454197 Wilms Tumor Study 0.602512 gen insulin growth 0.431312 complejos génicos 0.423036 anomalías renales 0.500059 gen nsd1 0.428186 Beckwith-Wiedemann padecerán 0.430165	Wilms Síndrome 0.573396 gen wt1 0.557769 gen fbxw7 0.42494 Lancet Oncol 0.427372 restos nefrógenos 0.582325 Spring Harbor Laboratory 0.432622 Cold Spring Harbor 0.432647 síndromes wagr 0.42334 gen ptch1 0.424282 efectos tardíos 0.471463 tumor wilms 0.630299 genes wt1 0.422664 dominio iiib 0.434344 antecedentes familiares 0.436654 Wilms anaplásico difuso 0.515326 Wilms esporádico 0.619115 mutaciones interruptoras 0.593507 gen wtx 0.481725 monoparental paterna 0.424225 primary malignant non-wilms 0.443665 gen tp53 0.452138 cánceres embrionarios.Las mutaciones 0.471064 insuficiencia renal 0.449112 células renales 0.428025	CLICK HERE
1885	National Cancer Institute	Html	es	Tratamiento de los cánceres poco comunes en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los cánceres poco comunes en la niñez como los cánceres de la cabeza y el cuello, el tórax, el abdomen, el aparato reproductor, la piel y otros.	Group Childhood Cancer 0.303634 Kadish Estadio Descripción 0.300271 cancer statistics 0.326488 pediatric rare tumors 0.992234 patients with relapsed 0.372754 cuadro clínico 0.354432 Advanced Solid Tumors 0.370423 estadificación posoperatoria 0.711901 GPOH Pediatric Rare 0.343984 cooperative study group 0.363939 Sin embargo 0.560837 ATA Task Force 0.473736 Pediatric Patients with 0.461297 Childhood Cancer Research 0.442875 cuáles pacientes 0.308117 Targeted Therapy Directed 0.368386 Treating Pediatric Patients 0.460472 or histiocytic disorders 0.361605 Internet ClinicalTrials.gov 0.45578 metástasis distantes 0.307395 Children's Oncology Group 0.570172 niños vs 0.418573 International Classification 0.392171 or refractory advanced 0.367754 tiroides medular nem2 0.365237	very rare tumors 0.299588 Refractory Advanced Solid 0.36854 carcinoma nasofaríngeo 0.834137 Pediatric Molecular Analysis 0.447293 Pediatric MATCH 0.923242 pediatric thyroid cancer 0.456559 End Results 0.382399 gammagrafía ósea 0.326636 BRAF V600E 0.354329 Childhood Cancer 0.803535 relapsed or refractory 0.373353 efectos tardíos 0.368787 ATA Pediatric Risk 0.307191 menudo metástasis 0.316315 Riesgo pediátrico intermedio 0.363674 rare pediatric tumors 0.355894 PDQ Tratamiento 0.348659 mutaciones braf v600e 0.349145 NCI-COG Pediatric Molecular 0.449773 gammagrafía diagnóstica 0.608069 Clin Oncol 0.421865 subgrupo xi 0.374046 with relapsed or 0.368469 european cooperative study 0.370036	CLICK HERE
2056	National Cancer Institute	Html	es	Píldoras anticonceptivas y el riesgo de cáncer	Hoja informativa acerca de la investigación sobre el riesgo de padecer cáncer de seno, de cérvix, de hígado y de ovarios por el uso de anticonceptivos orales.	oral contraceptives 0.31866 associated with 0.302278 hereditary ovarian cancer 0.307224 anticonceptivos orales 0.994735 combined estrogen-progestogen 0.301637 brca1 or brca2 0.301383 Carrier Cohort Study 0.301448 Disease Control 0.30169 tumores benignos 0.304773 femeninas naturales estrógeno 0.301612 Child Health 0.30166 Steroid Hormone Study 0.30142 IARC Monographs 0.301103 collaborative reanalysis 0.302305 ovarian cancer 0.328123 IARC Working Group 0.301458 Estados Unidos 0.301544 cervical cancer 0.319583 Hormonas Esteroides 0.301394 PubMed Abstract 0.41376 menor riesgo 0.304581 hormonal factors 0.3025 BRCA2 mutation 0.301911 Ovarian Cancer Clinical 0.303961 altas concentraciones 0.302166	efecto protector 0.30213 BRCA2 mutation carriers 0.301397 anticonceptivo oral combinado” 0.302358 alto riesgo 0.304148 Carcinogenic Risks 0.301908 Hunter DJ 0.301541 oral contraception 0.301256 Endocrine-Related Cancer 0.303484 benign liver tumours 0.301157 Epidemiology Biomarkers 0.302164 Cancer Research 0.303353 epidemiological studies 0.304291 National Institute 0.301484 estrogen-progestogen menopausal therapy 0.3011 hormonal contraceptives 0.302747 Human Development 0.301691 IARC commitment 0.301082 breast cancer 0.314784 cuello uterino 0.311204 associated with oral-contraceptive 0.301437 Cancer Institute 0.303378 Colditz GA 0.301768 Combined estrogen-progestogen contraceptives 0.301471 prospective study 0.301048	CLICK HERE
3422	National Cancer Institute	Html	es	Reconstrucción del seno después de una mastectomía	Hoja informativa que describe la reconstrucción del seno (mama) después de una mastectomía. Contiene información sobre las opciones quirúrgicas, los cuidados de seguimiento y los exámenes de detección del cáncer de seno después de la reconstrucción.	cirugía abdominal 0.39888 ley whcra 0.35286 Nipple-sparing mastectomy—is it 0.332063 Cordeiro PG 0.320216 colgajo siep 0.393996 Colgajo TRAM 0.39889 suficiente piel 0.387487 largo plazo 0.34858 large cell lymphoma 0.395571 reconstruction following surgery 0.356853 Reconstructive Surgery 0.417753 Colgajo SGAP 0.397479 Colgajo PAP 0.399861 Colgajo Latissimus 0.401399 PubMed Abstract 0.945047 Colgajo TUG 0.398937 colgajo diep 0.587224 Surgical Oncology Clinics 0.338406 Cirugía oncoplástica.  0.339864 La Cruz L 0.324776 NCI titulada Mamografías 0.32023 breast reconstruction 0.705756 colgajo igap 0.469394 pequeños trozos 0.3196 suficiente tejido 0.3777	colgajos ld 0.342761 Colgajo SIEA 0.398955 Da Lio A 0.329732 implantes de solución 0.348682 reconstruction after surgery 0.366752 therapy implications following 0.337385 suficiente volumen 0.324436 reconstrucción retardada 0.559365 Breast reconstruction after 0.445489 reconstruction after mastectomy 0.350953 Petit JY 0.31974 Breast Disease 0.377661 Cancer Rights Act 0.334748 Reviews Clinical Oncology 0.3359 oncoplastic breast-conserving surgery 0.341614 Total skin sparing 0.332343 técnica llamada 0.357673 sensibilidad conforme crecen y 0.339464 anaplastic large cell 0.394345 New England Journal 0.330568 ¿qué tipo 0.325566 physical therapy 0.407423 systematic reviews 0.354768 Surgical Oncology 0.355698	CLICK HERE
3599	National Cancer Institute	Html	en	The RAS Initiative	NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.	new therapies 0.393067 RAS 0.99043 RAS family 0.739708 long way 0.387894 oncogenic RAS 0.6688 primary focus 0.382845 RAS problem 0.663793 industry 0.314692 videos 0.313651 mouse retroviruses 0.388906 lab 0.314136 percent 0.362189 online forum RAS 0.726513 RAS reagents 0.661904 Douglas R. Lowy 0.440325 RAS genes 0.803577 Varmus’s vision 0.381489 RAS hub 0.667188 entire field 0.379292 mutations 0.318554 RAS oncogenes 0.710337 proteins 0.316387 Dear Colleagues 0.397967 National Cancer Institute 0.440589	pancreatic cancers 0.432526 NCI director 0.401396 RAS-related cancers 0.425588 events 0.31366 group 0.314948 innovative approaches 0.393563 goal 0.328772 biology 0.314898 academic researchers 0.385896 RAS Central 0.733488 virtual network 0.380109 headway 0.320561 Dr. Harold Varmus 0.45561 blog posts 0.37846 ras initiative 0.905093 mutant forms 0.396413 scientists 0.313674 useful tools 0.379773 human cancers 0.42887 fascinating problem 0.378178 colorectal cancers 0.432751 concerted effort 0.392419 time 0.314762	CLICK HERE
16776	National Cancer Institute	Html	es	Cancell/Cantron/Protocel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de Cancell/Cantron/Protocel como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Questionable methods 0.583285 NCI Tumor Cell 0.253187 Alternative Cancer Treatment 0.949939 Cancell Alternative Cancer 0.909029 physiological consequences 0.221271 Dills WL Jr 0.236274 Pedersen PL 0.220212 James V 0.220328 CA Cancer 0.715566 Instituto Nacional 0.460523 Tumor Cell Line 0.306478 Livingston-Wheeler therapy 0.223682 nombre cancell 0.23058 Estados Unidos 0.337461 mutational events that 0.237295 Cassileth BR 0.27252 Complementary Therapies 0.275875 tumour glycolysis 0.221381 Oncogenic alterations 0.222154 NCI-60 DTP Human 0.237422 Eastern District 0.221187 WW Norton 0.271304 Bioenerg Biomembr 0.223121 peso promedio 0.220355 District Court 0.221556	Alternative Medicine Handbook 0.357021 Edmund J 0.22088 United States 0.221128 bacteria p 0.221477 Semenza GL 0.221681 diabetes mellitus 0.223111 llamó entelev 0.224971 tipo cancell 0.228779 vía oral 0.22206 Winter Works 0.543066 Trends Biochem Sci 0.237977 critical role 0.221303 Dang CV 0.220582 Mathupala SP 0.220471 National Cancer Institute 0.327107 Aberrant glycolytic metabolism 0.237912 Permanent Injunction 0.223017 New York 0.262714 accessed april 0.557875 Cell Line Screen 0.307726 Physician Data Query 0.23188 Complete Reference Guide 0.33124 células primitivas resultantes 0.275971 Máxima concentración 0.230742	CLICK HERE